| Literature DB >> 25101488 |
Joseph B Santella1, Daniel S Gardner, John V Duncia, Hong Wu, Murali Dhar, Cullen Cavallaro, Andrew J Tebben, Percy H Carter, Joel C Barrish, Melissa Yarde, Stephanie W Briceno, Mary Ellen Cvijic, R Robert Grafstrom, Richard Liu, Sima R Patel, Andrew J Watson, Guchen Yang, Anne V Rose, Rodney D Vickery, Janet Caceres-Cortes, Christian Caporuscio, Daniel M Camac, Javed A Khan, Yongmi An, William R Foster, Paul Davies, John Hynes.
Abstract
High-affinity, functionally potent, urea-based antagonists of CCR1 have been discovered. Modulation of PXR transactivation has revealed the selective and orally bioavailable CCR1 antagonist BMS-817399 (29), which entered clinical trials for the treatment of rheumatoid arthritis.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25101488 DOI： 10.1021/jm5003167
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446